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Triple-negative breast cancer (TNBC) accounts for ∼15–20% of breast cancer (BC)
and has a higher rate of early relapse and mortality compared to other subtypes. The
Chemokine (C-C motif) ligand 5 (CCL5) and its signaling pathway have been linked to
TNBC. We aimed to investigate the susceptibility and prognostic implications of genetic
variation in CCL5 signaling genes in TNBC in the present study. We characterized variants
in CCL5 and that of six other CCL5 signaling genes (CCND1, ZMIZ1, CASP8, NOTCH2,
MAP3K21, and HS6ST3) among 1,082 unrelated Tunisian subjects (544 BC patients,
including 196 TNBC, and 538 healthy controls), assessed the association of the variants
with BC-specific overall survival (OVS) and progression-free survival (PFS), and correlated
CCL5 mRNA and serum levels with CCL5 genotypes. We found a highly significant
association between the CCND1 rs614367-TT genotype (OR = 5.14; P = 0.004) and
TNBC risk, and identified a significant association between the rs614367-T allele and
decreased PFS in TNBC. A decreased risk of lymph node metastasis was associated
with the MAP3K21 rs1294255-C allele, particularly in rs1294255-GC (OR = 0.47;
P = 0.001). CCL5 variants (rs2107538 and rs2280789) were linked to CCL5 serum
and mRNA levels. In the TCGA TNBC/Basal-like cohort the MAP3K21 rs1294255-G
allele was associated with a decreased OVS. High expression of CCL5 in breast tumors
was significantly associated with an increased OVS in all BC patients, but particularly in
TNBC/Basal-like patients. In conclusion, genetic variation in CCL5 signaling genes may
predict not only TNBC risk but also disease aggressiveness.
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INTRODUCTION
Triple-negative breast cancer (TNBC) accounts for 15–20%
of patients diagnosed breast tumors. TNBC tumors relapse
early after standard chemotherapy treatments and often develop
visceral metastases; it thus represents a subtype with the poorest
prognosis among all breast cancers. Others and our group
showed that Arab womenmight experience an early disease onset
and a preponderance of aggressive breast cancer phenotypes
(1). To some extent, high rates of TNBC may explain the poor
prognosis of BC diagnosed at a younger age in Arab populations.
Studies of Arab American women showed a similar BC pattern
as Arab women living in the Arab world (2, 3), suggesting that
a genetic component could be among the determining factors
associated with TNBC onset.
Immunity plays a crucial role in TNBC biology (4). TNBC,
and/or the basal-like subtype, is characterized by higher
mutational burden and lymphocyte density as compared to other
subtypes (and especially as compared with estrogen/progesterone
receptor positive tumors) (5). In TNBC, the density of
tumor infiltrating lymphocytes has been associated with
favorable prognosis (6, 7). Recently, the immune checkpoint
blockade Atezolizumab (monoclonal antibody against the
protein programmed cell death-ligand 1) has been approved
by the FDA for the treatment of metastatic TNBC based on
the positive results of a phase III trial (8). Furthermore, post-
treatment chemokine (C-C motif) ligand 5 (CCL5) increase
has been associated with responsiveness to immunotherapy
(Imiquimod) in breast cancer skin metastasis (9).
Our recent work demonstrated that CCL5, is strongly
implicated in BC pathogenesis, particularly in TNBC progression
(10). Hematopoietic CCL5 plays a pivotal role in recruiting
immune cells into the tumors (11, 12). The circulating CCL5
level variations, observed in BC patients, could reflect a
functional genetic variation in CCL5. Three Single Nucleotide
Polymorphisms (SNPs) in CCL5, namely rs2107538, rs2280788,
and rs2280789, are the most frequent SNPs associated with
inflammatory diseases (13). Thus far, potential association
between genetic variation in CCL5 and breast cancer has not
been investigated. Integrative genomics analysis, combining
information from GWAS studies on breast cancer involving
over 400,000 cases and over 400,000 controls, was performed by
Hicks et al. (14) to determine whether genes containing SNPs
associated with an increased risk of developing breast cancer
are associated with TNBC. Twelve out the 34 large-effect SNPs
associated with TNBC are located within genes involved in the
JNK, p38MAPK, NF-κB, and cAMP/PKA signaling pathways, all
of which regulate CCL5 levels in immune cells (15–17). These
findings prompted us to hypothesize that through their effect on
circulating CCL5 levels, functional polymorphism in both CCL5
and CCL5 signaling genes could be associated with TNBC.
In addition to the three SNPs of CCL5, we selected six SNPs
from the twelve associated with TNBC and involved in the
JNK, p38 MAPK, NF-κB, and cAMP/PKA signaling pathways.
These SNPs are tagged to CCND1, ZMIZ1, CASP8, NOTCH2,
MAP3K21, and HS6ST3. These genes encode proteins which
regulate CCL5 expression or themselves are regulated by CCL5.
CCND1 (cell-cycle regulator cyclin D1) encodes a cyclin protein
that is critical for the cell cycle. The CCL5/STAT/CCND1
signaling pathway plays an important role in the crosstalk
between epithelial cells and immune cells (18). ZMIZ1 (zinc
finger MIZ-type containing 1) encodes a transcription factor
which is a member of the Protein Inhibitor of Activated STAT
(PIAS)-like family of coregulators. Zmiz1 is important for T-cell
development and involved in NOTCH signaling (19), by which it
could regulate CCL5 expression (20).CASP8 encodes the Caspase
8 protein which plays a major role in cell apoptosis and regulates
NF-κB signaling (21). The functional association between CASP8
and CCL5 levels, secreted by immune cells, was shown in
a knockout mice model (22). NOTCH2 encodes a member
of NOTCH transmembrane receptor family. Dysregulation of
NOTCH signaling was involved in several diseases, including
BC (23). CCL5 expression is activated by NOTCH signaling
in the tumor microenvironment, both in cancer cells (20) and
tumor infiltrating lymphocytes (24, 25).MAP3K21 gene encodes
a member of the MAPK pathway (also known as MLK4).
MAP3K21 serves as an activator of NF-κB signaling (26); a
major pathway for inducing CCL5 expression (27). HS6ST3
encodes a member of Heparan sulfate (HS) involved in several
cellular and molecular processes, including cell proliferation and
differentiation (28). By regulating IGFR1 expression, HS6ST3
could affect CCL5 expression (29, 30).
Based on the abundant evidence of the role of CCL5 in
TNBC, we evaluated, in this study, the association of 9 SNPs,
reflecting the genetic variation in CCL5 signaling genes, with
TNBC susceptibility and prognosis.
MATERIALS AND METHODS
Patients and Controls
A total of 1,082 unrelated subjects with high quality of genomic
DNA, comprising 544 breast cancer patients, including 196
TNBC, and 538 healthy controls, were included in this study.
Controls and patients were selected from the same ethnic group
living in the middle coast of Tunisia. Only patient/control
subjects who have ancestors up to three generations back who
were natives of Tunisia and have lived for at least 10 years in
Tunisia were included in the study. The participation rate for
patients and controls exceeded 90 and 75%, respectively.
All patients included in this study had primary breast cancer,
with unilateral breast tumors and no family history of the disease.
The diagnosis of cancer was confirmed by histopathological
analyses. The mean age of patients was 48.8 ± 10.9 years. After
completion of treatment, patients had regular visits every 3–4
months in the first 2 years, every 6 months in the following
3 years and annually thereafter. At each visit patients were
checked for symptoms and undergo a physical examination,
mammography, chest X-ray and abdominal ultrasound were
performed annually. During follow up, both locoregional and
distant tumor recurrence were diagnosed as relapse based
on clinical, radiological and histological findings. The median
follow-up was 55 months (range, 1–175 months). Data on
each patient were collected from the department of Radiation
Oncology of Sousse Hospital (Sousse, Tunisia) between 2002
and 2016. A detailed description of the clinical/pathological
characteristics is summarized in Table 1.
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A total of 538 healthy women with a mean age of 48 ±
14 years were recruited as controls. They are typically either
outpatients seen for vaccination or blood donation or friends or
non-biological relatives of cancer patients with no evidence of
any personal or family history of cancer (or other serious illness).
Samples from healthy controls were collected consecutively
between 2004 and 2016 andwere age–groupmatched to the cases.
After a written consent was obtained, each participant
(patient/control) had a blood sample taken and was interviewed
using a questionnaire. The questionnaire has been tested,
standardized and endorsed by the oncologists involved in the
recruitment of patients with breast cancer. This questionnaire
included a collection of epidemiological and lifestyle data
and a “genetic” part examining consanguinity of parents and
familial history with detailed data on all first and second-
degree relatives with breast cancer (age, disease status). Detailed
clinical-pathologic characteristics of the tumor are included
as well. For all patients with breast cancer, early treatment
response was assessed at 3- and 6-months post-treatment and
graded as complete, or partial or poor/disease progression. The
blood samples from patients were taken before initiation of
any treatment.
Approval for the study was given by the Weill Cornell
Medicine-Qatar Ethics Committee. Both patients and controls
gave their written consent to participate in the study.
TCGA Affymetrix Human SNP 6.0 array genotyping calls of
patient germline DNA were downloaded from NCI’s Genomic
Data Commons (https://gdc.cancer.gov). SNPs were filtered to
eliminate >5% missing genotypes, and individuals with >5%
missing genotypes were also removed. Individuals were clustered
into ancestry groups using principal components analysis and
PAM clustering, and samples which had heterozygosity values
that were >3 standard deviations from the mean heterozygosity
from the same ancestral populations were also eliminated.
Only one sample per individual were included, with blood-
derived samples and samples with higher call rates preferentially
retained. SNPs that deviated from the expectation under Hardy-
Weinberg equilibrium (p < 1 × 10−6) in analysis of the largest
ancestral group were also dropped (though SNPs previously
associated with any cancer as reported in the GWAS catalog
with p < 5× 10−8 were not eliminated since they may deviate
from HWE in cancer cases). SNPs with minor allele frequency,
MAF < 0.5% were excluded, and duplicate SNPs with identical
genomic first positions were removed. Palindromic SNPs were
excluded prior to stranding. Finally, we checked for close
relative pair-based analyses in PLINK1.9 and dropped one of
each of these relative pairs. Variants were imputed through
Minimac 3 selecting the panel of 1000 Genome Phase 3v5 using
mixed population. The final dataset includes 163 Basal-like/TN
breast cancer patients with available overall survival information,
which were used in the present analysis. Annotated Germline
TCGA Exome data (31) were used to retrieve CCR5 delta-
32 information.
SNP Selection and Genotyping
We selected the three of themost studied SNPs ofCCL5 located in
the promoter region of the CCL5 gene. We also selected six SNPs
from breast cancer GWAS studies (14). The six SNPs containing
TABLE 1 | Clinicopathologic characteristics of the breast carcinoma patients.
Characteristics Cases
Age range 23–91

























Estrogen receptor (ER) status*
Positive 277
Negative 222











*Some data are missing.
genes are all involved in signaling pathways that can regulate
CCL5 levels. The SNP information is summarized in Table S1.
Genotyping was performed using the TaqMan R© SNP genotyping
assays on Applied Biosystems QuantStudio 6 Flex Real-Time
PCR System (Foster City, California, United States).
Enzyme-Linked Immunosorbent Assay
(ELISA)
A specific ELISA (Human CCL5/RANTES Quantikine ELISA
Kit, R&D Systems, Minneapolis, Minnesota, United States) was
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used to determine CCL5 levels in serum before cancer treatment
with a calorimeter (CLARIOstar, BMG LABTECH, Ortenberg,
Germany) at a wavelength of 405 nm. Three hundred-sixteen
breast cancer patients whose serum were available, including 128
TNBC patients, were tested in this study.
In silico Analysis of CCL5 Gene Expression
The allele specific gene expression was assessed at Genotype-
Tissue Expression Portal (GTExPortal) (https://gtexportal.org/
home/) (32) and eQTL Catalog (https://eqtl.onderzoek.io) (33).
The cancer survival analysis with TCGA data was performed
using UCSC XENA (https://xena.ucsc.edu) and for that with
the gene expression array data was performed using KM
plotter (http://kmplot.com) (34). Correlation between CCL5
and markers of stemness (cancer stem cells and normal stem
cells) and epithelial to mesenchymal transition (EMT) markers,
was performed by using a normalized RNA matrix, described
elsewhere (35). The selection of markers was based on current
literature (36).
RNA Extraction and qPCR Quantification
RNAwas extracted from frozen blood using PAXgene Blood RNA
Kit (Qiagen, Germantown, Maryland, United States) using the
following protocol (37). 300 µl of blood sample was dispensed
into 830 µl PAXgene reagent. The mixture was incubated for
overnight at room temperature and spun for 3min at 5,000 g.
After washing with 500 µl RNase-free water, the pellet was
resuspended in 350 µl Buffer BR1 and incubated with 300 µl
Buffer BR2 (binding buffer) and 40 µl proteinase K for 10min
at 55◦C in a shaker-incubator at 1,400 rpm. The lysate was
transferred into a PAXgene Shredder spin column placed in
a 2ml processing tube and centrifuged for 3min at 18,000 g.
The flow-through fraction was mixed with 350 µl ethanol,
transferred to a PAXgene RNA spin column and centrifuges for
1min at 18,000 g. After washing the column with Buffer BR3
(washing buffer I), samples were incubated with 80 µl of DNase I
incubation mix (10 ul DNase I with 70 ul Buffer RDD) for 15min
at room temperature. PAXgene RNA spin columns were washed
with Buffer BR3 and 2 times of Buffer BR4 (Washing buffer II).
RNA was eluted with 40 µl Buffer BR5 (elution buffer).
Total RNA was reverse-transcribed into cDNA using
SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad,
California, United States) following the manufacturer’s protocol.
CCL5 mRNA levels were measured by qPCR with a GoTaq R©
2-Step RT-qPCR System (Promega, Madison, Wisconsin,
United States) for SYBR Green-based detection. The qPCR
primers for CCL5 are 5′-CCAGCAGTCGTCTTTGTCAC-
3′ and 5′-CTCTGGGTTGGCACACACTT-3′. The HPRT1
gene was used as a reference and primer sequences
are 5′-TGACACTGGCAAAACAATGCA-3′ and 5′-
GGTCCTTTTCACCAGCAAGCT-3′. Two hundred and
twenty-six mRNA samples were tested in this study.
Statistical Analyses
Hardy-Weinberg equilibrium in both patient and control groups
were tested using the Chi-square test. According to the general
genotype model, risk association between the genotypes and
breast cancer susceptibility and tumor characteristics were
estimated by a crude odds ratio (OR) with 95% confidence
intervals (95% CI) using the unconditional logistic regression
analysis with genotypes coded additively (as 0, 1, or 2 copies
of one of the alleles). The association was then adjusted for age
and menopausal status. A P-value of <0.05 was required for
statistical significance.
The statistical analysis was performed using the Epi-Info
statistical program (version 5.01; CDC, Atlanta, GA, USA).
Breast cancer specific overall survival (OVS) was defined as the
time from the date of diagnosis to death from breast cancer or
to last contact. Progression-free survival (PFS) was defined as the
time from the date of diagnosis to distant metastasis, relapse and
death from BC or to last contact. The survival curves were plotted
according to Kaplan and Meier. Differences between groups
were calculated by the log rank test. For PFS survival of TNBC
patients between rs614367 risk allele carriers and non-risk allele
carriers, a multivariate Cox Regression analysis was performed
for age, menopausal status, tumor stage, SBR grade, lymph node
status and pathologic classification using SPSS statistic software
(Version 25.0, IBM Corporation).
RESULTS
Genetic Variation in CCL5 Signaling Genes
as Risk Factors for Breast Cancer and for
TNBC
Genotype distribution of all 9 SNPs in controls did not
deviate from Hardy-Weinberg equilibrium (Table S2, P > 0.05).
The rs2280788-C allele is very rare in our study population
compared to that found in the 1000 Genome and HapMap. The
linkage disequilibrium (LD) between CCL5 rs2107538 and CCL5
rs2280789 was calculated using SHEsis (38). In controls, D′ is
0.763 and r2 is 0.407; in cases, D′ is 0.906 and r2 is 0.488. These
results indicate a strong LD between these two loci. However,
the allele frequencies between these two loci are quite different
(Table 2). Therefore, we continued the analysis of these two
loci separately.
A significant increase in the CCL5 rs2107538-T and
HS6ST3 rs1924587-C allele frequencies was observed in
the patient group compared to the controls (P = 0.0007
and 0.009, respectively, Table 2). The OR of breast cancer
associated with the CCL5 rs2107538-T/T genotype was 2.74
(P = 0.004) and that of HS6ST3 rs1924587-C/C genotype
was 1.52 (P = 0.021). The allelic frequency of the CCND1
rs614367-T was higher in patients with breast cancer compared
to control subjects resulting in a significantly positive OR
associated with this allele (OR = 1.38, P = 0.032). This
association was found to be specifically confined to the
CCND1 rs614367-T/T homozygous genotype (OR = 3.64,
P = 0.016). In addition, a significant association was
found between breast cancer and the CCL5 rs2280789-
G/G homozygous genotype (OR = 5.52, P = 0.019). After
adjustment for the potential confounders, including age
and menopausal status, the association of CCL5 rs2107538-
C/T genotype (P = 0.034), CCL5 rs2107538-T/T genotype
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TABLE 2 | Association of 9 SNPs of the CCL5 and CCL5 signaling pathway with breast carcinomaa risk.
SNP Gene Genotype Risk allele frequency Heterozygotesb Homozygotesc Per risk allele
Cases (n = 544) Controls (N = 538) OR (95%CI) P OR (95%CI) P OR (95%CI) P
rs2107538 CCL5 C/T 0.206 0.149 1.36 (1.04–1.77) 0.025** 2.74 (1.337–5.60) 0.004** 1.47 (1.17–1.84) 0.0007
rs2280788 CCL5 G/C 0.009 0.002 2.67 (0.70–10.11) NS 3.0 (0.12–73.81) NS 3.32 (0.91–12.09) 0.054
rs2280789 CCL5 A/G 0.132 0.109 1.13 (0.85–1.51) NS 5.52 (1.12–23.69) 0.019* 1.25 (0.96–1.62) 0.092
rs614367 CCND1 C/T 0.13 0.099 1.18 (0.87–1.59) NS 3.64 (1.19–11.16) 0.016** 1.38 (1.02–1.71) 0.032
rs704010 ZMIZ1 C/T 0.321 0.288 1.01 (0.79–1.30) NS 1.51 (0.99–2.31) NS 1.15 (0.96–1.38) NS
rs1045485 CASP8 G/C 0.136 0.124 1.05 (0.79–1.41) NS 1.37 (0.62–3.03) NS 1.10 (0.85–1.41) NS
rs1124933 NOTCH2 G/A 0.319 0.339 0.80 (0.62–1.03) NS 0.90 (0.61–1.31) NS 0.90 (0.75–1.07) NS
rs1294255 MAP3K21 G/C 0.425 0.411 1.0 (0.77–1.31) NS 1.09 (0.78–1.52) NS 1.04 (0.88–1.23) NS
rs1924587 HS6ST3 G/C 0.427 0.369 1.33 (1.02–1.74) 0.032* 1.52 (1.07–2.17) 0.021** 1.26 (1.06–1.49) 0.009
CI, confidence interval; OR, odds ratio.
a Including all breast carcinoma patients.
bHeterozygotes compared to homozygotes of reference allele.
cHomozygotes of risk allele compared to homozygotes of reference allele.
The chi-square test with was used to determine whether significant differences (P-value) were observed when patient group was compared with control subjects. Significant P-values
are in bold cases.
**The association remains significant after age and menopausal status adjustment.
*Not significant after age and menopausal status adjustment.
(P = 0.011), CCND1 rs614367-T/T genotype (P = 0.021) and
HS6ST3 rs1924587-C/C genotype (P = 0.019) with BC risk
remained significant.
In order to identify a specific association between certain
CCL5 signaling pathways and TNBC, we stratified the 544
patients with breast cancer according to the breast cancer
subtype, namely TNBC and hormone receptor positive breast
cancer (HRBC). A highly and significant increase in risk of
TNBC compared to controls, but not of HRBC, was observed
in subject carriers of the CCND1 rs614367-T/T homozygous
genotype (OR = 5.14, P = 0.004, Table 3 and Table S3). Among
the 9 SNPs, only the CCND1 rs614367-T/T genotype showed a
strong and specific association with TNBC.
TheCCL5 rs2107538-T allele was significantly associated with
both TNBC and HRBC but the OR associated with HRBC was
higher and more significant (OR = 1.45, P = 0.015 in TNBC
compared to OR = 1.80, P = 0.0001 in HRBC). An increased
risk of HRPC was found associated with the rs1924587-C allele
(OR= 1.33, P= 0.006) and was confined to the homozygousC/C
genotype (OR= 1.7, P= 0.012). A slightly significant association
with TNBC was also observed in carriers of the heterozygous
G/C genotype (OR= 1.51, P = 0.025).
Both CCL5 rs2280788-GC and CCL5 rs2280789-GG showed
a slightly significant association with TNBC (OR = 4.98,
P = 0.041; OR = 5.72, P = 0.024, respectively). Carriers of the
rs2280789-G allele had a marginal increase in the risk for HRBC
(OR= 1.36, P = 0.048).
After adjustment for the potential confounders, including age
and menopausal status, the association of CCND1 rs614367-T/T
genotype (P= 0.015) with TNBC risk and both of the association
of CCL5 rs2107538-T/T genotype (P = 0.004) and HS6ST3
rs1924587-C/C genotype (P = 0.004) with HRBC risk remained
significant, and the association ofCCL5 rs2107538-C/T genotype
(P = 0.049) with HRBC risk was suggestive.
Prognostic Significance of Genetic
Variation in the CCL5 Signaling Pathway
Table S4 lists the clinical and pathological characteristics. The
distribution of the clinical and pathological markers was in
agreement with previously reported data, indicating that our
cohort was representative of breast cancer patients. Progression-
free survival (PFS) rates were estimated and compared by
univariate analysis based on the clinical and pathological
parameters. Significant associations were found for: clinical
tumor size, lymph node status, and tumor grading with PFS. No
significant differences were observed for age.
We investigated the potential association of 9 SNPs associated
with the CCL5 signaling pathway and the clinical and
pathological characteristics of breast cancer in our cohort. As
shown in Tables S5, S6, the rs1294255-C allele was found
more frequently in patients with no lymph-node metastasis;
this resulted in a significantly negative OR associated with
heterozygous rs1294255-G/C (OR = 0.47; P = 0.001 compared
to GG genotype).
As shown in Figure 1A, the progression-free survival (PFS)
was significantly shorter in the group of TNBC patients carrying
theCCND1 rs614367-T allele. The estimated 5- and 10-years PFS
rates in the groups of TNBC patients carrying or not the CCND1
rs614367-T allele were, respectively, 78 and 50% vs. 92 and 66%
(log rank test, P = 0.014). Furthermore, a multivariate analysis
was performed for age, menopausal status, tumor stage, SBR
grade, lymph node status and pathologic classification. As shown
in Figure S1, the survival rates showed a difference trend between
patients with and without the CCND1 rs614367-T allele, but the
difference did not reach statistical significance (P = 0.359).
The limited number of breast cancer specific death events
in our cohort hampered the search for a potential association
between the 9 SNPs and OVS. The analysis of the TCGA dataset,
which included 163 TNBC/Basal-like patients with available
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TABLE 3 | Association of 9 SNPs of the CCL5 and CCL5 signaling pathway with triple negative breast cancer risk.
SNP Gene Genotype Controls Cases Heterozygotesa Homozygotesb Per risk allele
N = 538 N = 196 OR (95%CI) P OR (95%CI) P OR (95%CI) P
rs2107538 CCL5 CC 389 125 1.42 (0.99–2.03) 0.055* 2.26 (0.89–5.75) 0.079* 1.45 (1.07–1.95) 0.015
CT 138 63
TT 11 8
rs2280788 CCL5 GG 535 192 4.98 (0.91–27.41) 0.041* 2.49 (0.05–125.72) NS 4.94 (0.9–27.07) NS
GC 3 4
CC 0 0
rs2280789 CCL5 AA 423 148 1.11 (0.75–1.65) NS 5.72 (1.04–31.53) 0.024* 1.254 (0.88–1.78) NS
AG 113 44
GG 2 4
rs614367 CCND1 CC 435 148 1.22 (0.81–1.83) NS 5.14 (1.49–17.82) 0.004** 1.48 (1.04–2.09) 0.027
CT 99 41
TT 4 7
rs704010 ZMIZ1 CC 271 94 1.02 (0.72–1.44) NS 1.54 (0.88–2.69) NS 1.16 (0.9–1.49) NS
CT 224 79
TT 43 23
rs1045485 CASP8 GG 416 151 0.97 (0.64–1.46) NS 1.5 (0.55–4.13) NS 1.06 (0.75–1.5) NS
GC 111 39
CC 11 6
rs1124933 NOTCH2 GG 233 96 0.73 (0.51–1.03) NS 1 (0.64–1.57) NS 0.93 (0.73–1.19) NS
GA 241 72
AA 64 28
rs1294255 MAP3K21 GG 192 76 0.83 (0.72–1.19) NS 0.99 (0.63–1.56) NS 0.97 (0.77–1.23) NS
GC 245 80
CC 101 40
rs1924587 HS6ST3 GG 216 63 1.51 (1.05–2.17) 0.025* 1.13 (0.67–1.91) NS 1.15 (0.91–1.46) NS
GC 243 107
CC 79 26
CI, confidence interval; OR, odds ratio.
aHeterozygotes compared to homozygotes of reference allele.
bHomozygotes of risk allele compared to homozygotes of reference allele.
The chi-square test was used to determine whether significant differences (P-value) were observed when TNBC patient group was compared with control subjects. Significant P-values
are in bold cases.
**The association remains significant after age and menopausal status adjustment.
*Not significant after age and menopausal status adjustment.
FIGURE 1 | Breast cancer-specific progression-free survival of 196 TNBC patients according to the presence or absence of the CCND1 rs614367-T allele (A) and
specific 10-years overall survival of 163 TNBC patients from the TCGA dataset according to the presence or absence of MAP3K21 rs1284255-G allele (B).
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OS and genotype information, revealed a significant association
between the MAP3K21 rs1294255-G allele and OVS. As shown
in Figure 1B, the OVS was significantly shorter in the group
of TNBC/Basal-like patients carrying the MAP3K21 rs1294255-
G allele. The estimated 10-years OVS in the groups of TNBC
patients with or without the MAP3K21 rs1294255-G allele was
<80 and 100%, respectively (log rank test, P = 0.043). Similarly,
CCL5 rs2107538-T allele showed a suggestive association with
reduced OVS in TNBC patients (Figure S2). No statistically
significant associations with OS were observed for the other
seven polymorphisms.
Functional Implications for Breast Cancer
and TNBC Risk Variants Associated With
CCL5 Expression
To assess whether the 9 SNPs were associated with changes in
the expression of CCL5 and/or their tagged genes, we performed
eQTL (expression quantitative trait loci) analyses using GTEx
and NESDA and NTR data. In a dose-dependent manner,
the breast cancer risk alleles CCL5 rs2280789-G and CCL5
rs2107538-T were predictors of low levels of CCL5 expression
in whole blood and lymphocytes of GTEx dataset (P = 7
× 10−6 and 6 × 10−8, respectively) (Figures S3A,B). The
rs1294255-G allele was associated with low levels of MAP3K21
expression (Table S7). The association between CCL5 variants
andCCL5 expression was confirmed by quantifyingCCL5mRNA
in 226 blood samples from our study population. qPCR analysis
suggested thatCCL5 rs2280789-G andCCL5 rs2107538-T alleles
associated with low levels of CCL5mRNA (Figures 2A,B).
The CCL5 levels in serum before cancer treatment were
correlated with patients’ CCL5 genotypes. As shown in
Figures 2C,D, the breast cancer risk alleles CCL5 rs2280789-
G and CCL5 rs2107538-T were highly associated in a dose-
dependent manner with low levels of CCL5 in sera of patients
with breast cancer (all patients without subtype stratification).
Similar findings were observed in sera of TNBC patients
(Figures 2E,F). The size effect of CCL5 rs2107538 was higher
in patients with TNBC than that observed in all patients with
breast cancer. No significant difference in CCL5 levels was
found between sera of control subjects and that of cancer
patients (Figure S4).
Taken together, these findings suggest a potential impact
of CCL5 expression levels on disease progression and clinical
outcome. We addressed this hypothesis by assessing the
correlation between CCL5 expression in breast tumors and
disease survival using the TCGA dataset. As shown in
Figure S5A, high levels of CCL5 expression predict a better
survival in breast cancer patients (all subtypes included). This
correlation did not reach statistical significance in cases with
TNBC (likely duo to the limited sample size), but a trend toward
higher survival rates was seen for TNBC tumors expressing high
levels of CCL5 (Figure S5B). Further, we used the KM plotter
platform (including a higher number of samples, i.e., the ones for
which gene expression array were available either from TCGA
or deposited in GEO) to evaluate an association between CCL5
expression and breast cancer and TNBC patients’ survival. High
levels of CCL5 expression correlated with a highly significant
increase effect for TNBC patients’ survival (Figure S5D). The
estimated 5-years survival probabilities in the TNBC tumors
expressing high or low levels of CCL5 were 0.88 and 0.63,
respectively (log rank test, P = 0.00045). A similar observation
was made when the analysis was performed on the unstratified
breast cancer group (Figure S5C); here CCL5 expression had
a less significant effect on the survival probabilities and the
hazard ratio (HR) was higher compared to that observed in
cases with TNBC (0.66 vs. 0.30). The estimated 5-years survival
probabilities in the unstratified breast cancer tumors expressing
high or low levels of CCL5 were 0.90 and 0.78, respectively (log
rank test, P = 0.0093). Notably, the levels of CCL5 expression
had no significant effect on non-TNBC patient survival (data not
shown) in line with the predominant prognostic effect of tumor
infiltrating lymphocytes observed prevalently in TNBC.
We next assessed in the TCGA cohort the potential association
between CCL5 expression andmarkers of stemness and epithelial
to mesenchymal transition (EMT) markers. As shown in
Figure 3, CCL5 expression correlates at some extent with
markers of stemness (cancer and normal stem cells) and with
EMTmarkers in the analysis including all the intrinsic molecular
breast cancer subtypes. However, such correlations were found
particularly weak in the case of basal-like subtype, in which
CCL5 was inversely correlated with mesenchymal markers. This
might be explained by the pleiotropic role of CCL5, from one
side being involved in TNBC pathogenesis, and from the other
side mediating protective anti-tumor immunity via a positive
immunologic loop resulting in lymphocyte recruitment through
the interaction with its ligand CCR5 (co-expressed, together with
CXCR3 by activated lymphocytes and NK cells). The inverse
correlation between mesenchymal markers and CCL5 in the
TNBC/basal-like subtype is also in line with the protective role
of CCL5 observed in this group of tumors.
We also assessed the survival impact of a functional
deleterious germline polymorphisms of the CCL5 receptor
CCR5 (132 polymorphisms) in the TCGA cohort. The
CCR5-132 polymorphism consists of a 32-base deletion
encoding a truncated protein, which is not expressed
on the cell surface (11) and is strongly associated with
HIV resistance (in the homozygous status) or disease
progression (in the heterozygous status) (39). No differences
or trends were observed in term of overall survival,
either in the entire BC cohort or in the basal-like cohort
(Figure S6), when patients were stratified according to the
CCR5-132 status.
DISCUSSION
Given their crucial role in inflammatory diseases, chemokines
were the subject of extensive study for several decades. Their role
in recruiting immune cells to the tumor microenvironment made
them an attractive potential target for cancer treatment. Among
chemokines, CCL5 is relatively well-studied in cancers including
breast cancer (40). However, knowledge of CCL5 implications
with regard to cancer susceptibility remains elusive.
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FIGURE 2 | Quantification of CCL5 mRNA levels in blood cells and serum CCL5 in of breast cancer and TNBC patients. CCL5 mRNA levels in blood cells of breast
cancer patients according to the genotypes of CCL5 rs2280789 (A) and CCL5 rs2107538 (B). CCL5 serum levels in 312 patients with breast cancer and in 128
patients with TNBC according to the genotypes of CCL5 rs2280789 (C,E) and CCL5 rs2107538 (D,F).
In the present study, we assessed the BC susceptibility of
CCL5 polymorphisms, including rs2107538, rs2280788, and
rs2280789. The BC susceptibility locus CCL5 rs2107538 in
our cohort was significantly associated with the risk for both
TNBC and HRBC; the other breast cancer susceptibility locus
rs2280789 was associated with an increased risk for TNBC
but only had a marginal effect on HRBC, while rs2280788
had a weak association with TNBC risk. We also assessed BC
susceptibility of 6 SNPs in CCL5 signaling genes and found that
CCND1 rs614367 was associated specifically with TNBC risk.
HS6ST3 rs1924587 was preferentially associated with HRBC
risk. MAP3K21 rs1294255 was associated with lymph-node
invasion of breast tumors. For certain SNPs, we observed the
association between BC and the allele risk in a dose-dependent
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FIGURE 3 | The correlation between CCL5 expression and the expression of markers of stemness and Epithelial-Mesenchymal Transition (EMT) markers. IMS,
intrinsic molecular subtype; Lum, luminal.
manner. This is the case of rs2107538 and rs1924587. However,
for other SNPs, the association was found confined either to
the heterozygous or to the homozygous genotype. This could be
linked to the low prevalence of the hetero/homozygous genotype
in the study population. TNBC specific SNP rs614367 was
associated with prognosis in a BC subgroup-TNBC but not in all
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breast cancer patients.We also showed the functional implication
of CCL5 breast cancer susceptibility locus and correlated the
risk alleles of CCL5 SNPs with low levels of serum CCL5.
Furthermore, we performed in silico analysis and found that low
CCL5 expression predicted a poor survival in BC and TNBC.
CCL5, which is originally known as RANTES (regulated
on activation, normal T cell expressed and secreted), directs
leukocytes to migrate into damaged or infected sites upon
an inflammatory insult. In addition, CCL5 is essential to
maintaining CD8T cell function during chronic infection (41).
It could be expected that high CCL5 levels at the tumor site
would result in the recruitment of CD8+ T cells and sustain
their cytotoxic capability against tumor cells. CCL5 expression
is indeed associated with accumulation of CD8+ infiltrating
T cells and associated with a favorable prognosis in colon
cancer (42) and breast cancer (43). The risk allele of two
SNPs in CCL5 gene corresponds with a lower CCL5 expression,
which leads to a depletion of CD8+ infiltrating T cells, and,
impairment of CD8+ T cell function and thus a higher risk of
malignancy. Nevertheless, we did not observe any significant
association between CCL5 polymorphism and survival or disease
characteristics, except a suggestive effect of rs2107538-T allele
on TNBC patient survival. This indicates that other type(s) of
immune cells might play a dominant role in disease progression
other than CD8+ T cells. Our in silico analyses, assessing the
prognosis value of CCL5 expression, showed that low CCL5
expression predicted a poor survival in BC and TNBC. These
findings are in agreement with certain previous reports (43, 44)
but contradict others (13). These discrepancies could be due
to several reasons including the size of the study population.
Unlike most of the previous studies, in the current study we
performed analyses on large public datasets (34). Furthermore,
we assessed the CCL5 expression in tumor specimen harboring
both tumor and stroma cells which provides a more accurate
assessment of the CCL5 effects not only on tumor cells but also on
tumor microenvironment and tumor-infiltrating immune cells.
Conversely, several previous reports limited their assessment of
the effects of CCL5 expression on tumor cell behavior which
could lead to biased conclusions.
Our study is limited by the relatively few deaths in patients
which limited the power for survival analyses. To address this
limitation, we analyzed TCGA data which strengthened our
findings and revealed a significant association between the
MAP3K21 rs1294255-G allele and OVS in TNBC patients.
One of the goals of this study was to identify TNBC
susceptibility SNPs given that immune pathways and activities
were elevated in TNBC compared to non-TNBC. However,CCL5
polymorphisms were not preferentially associated with TNBC,
indicating that CCL5 also plays an important role in non-TNBC.
CCL5 has been implicated in luminal type breast cancer by
modulating the phenotype of CD4+ T cells (45) and in ER-
positive breast cancers by promoting macrophage influx (46).
The clinically established BC Intrinsic subtype classifiers, PAM50
(47) and claudin-low predictor (48), do not contain CCL5 gene.
All the above suggest a universal contribution of CCL5 in BC
regardless of the subtypes. Tumor-derived CCL5 was detected
in many clinical specimens and BC-derived cell lines, and were
considered to promote BC aggressiveness (13). However, we
and others showed that tumor-derived CCL5 expression did
not significantly promote mammary carcinoma growth (10,
49), but the hematopoietic CCL5 played the major role in
BC progression by regulating myeloid cells or macrophages in
different subtype of BC (10, 50). Two recent studies suggested
that intertumoral CCL5 level determined the recruitment of
CD8+ T-cell in TNBC (43, 51). CCL5 might influence tumor
growth by regulating different tumor-infiltrating immune cells
in different subtypes of BC. Compared to CCL5 rs2107538, the
association of CCL5 rs2280788 and CCL5 rs2280789 was not
that significant. However, the OR of the latter two are often
relatively high even if only a slight significance or a suggestive
significance. Unlike common variants with low penetrance, these
two variants seem to have a medium penetrance in breast cancer.
We showed that CCND1 rs614367 was associated with a
strong and specific increased risk for TNBC, and also had
prognostic value only for TNBC. CCND1 rs614367 is one
of the strongest breast cancer risk loci identified by GWAS
studies; however, its specific association with TNBC has not been
identified. Replication of these findings in other populations will
be of interest to determine whether the association of theCCND1
rs614367 with TNBC can be generalized. In GWAS studies,
rs614367 was usually tagged to the CCND1 gene, which encodes
cyclin D1, a central component in the cell cycle that could be
regulated by estrogen. Although CCND1 is well-established as a
cancer driver gene (52), it seems that CCND1 is an ER-positive
breast cancer marker (53). FGF19 is one of its another nearby
gene, and FGF19 and its receptor FGFR4 were strongly associated
with the basal-like subtype of breast cancer (54). However, our
in-silico analyses did not show any allele specific effect on these
genes’ expression. It will be of interest to further explore the
functional implications of rs614367 like its potential long-range
regulation or its association with non-coding RNA.
We also showed that HS6ST3 rs1924587 was preferentially
associated with HRBC risk. HS6ST3 could promote breast cancer
cell proliferation by upregulating IGF1R expression (29). It
has been shown that IGF1R inhibits CCL5 expression and
consequently reduces the chemotactic movement of CD8+ T
lymphocytes (30). Taken together these findings suggest that
through IGF1R, HS6ST3 could affect both CCL5 levels and tumor
infiltrating CD8+ T lymphocytes behavior. This agrees with our
finding showing that low levels of CCL5 expression associated
with poor prognosis of BC. It is worth noting that IGF1R is
abundant in HRBC but not in TNBC (55) which agrees with
our current finding showing the preferential association between
HS6ST3 rs1924587 and HRBC risk and could also explain the
predominant role of CCL5 in HRBC.
Analysis of multiple datasets indicates that high expression
of MAP3K21 is associated with a poor survival in breast cancer
(56), and, the C allele of rs1294255 is associated with a low
expression ofMAP3K21 (Table S7). These findings are consistent
with our analysis of the TCGA breast cancer dataset showing that
rs1294255-G allele associated with poor prognosis. In the present
study, we could not replicate the association, shown by GWAS,
between rs1294255 and TNBC risk, but rather we observed that
the rs1294255-C allele was found more frequently in patients
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with no lymph-node metastasis resulting in a significantly
negative OR associated with the heterozygous rs1294255-CG.
Although the GWAS studies in Caucasians and the meta-
analysis could lead to the discovery of SNPs associated
with breast cancer, discovery studies and independent
validation in different population are needed given the
ethnic specificity and environmental exposure. For example,
TNBC is over-expressed in African-American populations
(57) as well as Arab populations. However, the correlated gene
expression data and genotyping data are not available for these
two populations.
In conclusion, the results of this study suggest that genetic
variation in CCL5 and the CCL5 signaling pathway might have
not only susceptibility but also prognostic implications for
TNBC. Furthermore, this work adds to the evidence that CCL5
and its mediators play a critical role in the process of TNBC
development and aggressiveness.
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